NVAX · XBRL financial data

Novavax financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (NVAX's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021†Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	476	1,146	1,982	984	682	1,123
Revenue from contracts with customers	—	—	1,982	984	682	1,123
Cost of revenue	0	0	903	344	203	73
Research and development	747	2,535	1,235	738	391	342
Selling, general and administrative	—	—	489	469	337	157
General and administrative	145	298	489	469	—	—
Operating income (loss)	(417)	(1,687)	(645)	(567)	(249)	453
Interest income	—	—	—	20	37	30
Interest expense	15	21	20	14	20	23
Other income (expense)	13	(8)	11	38	40	41
Income tax expense (benefit)	0	29	4	2	11	2
Net income (loss)	(418)	(1,744)	(658)	(545)	(187)	440
Earnings per share, basic USD per share	(7.27)	(23.44)	(8.42)	(5.41)	(1.23)	2.72
Earnings per share, diluted USD per share	(7.27)	(23.44)	(8.42)	(5.41)	(1.23)	2.58
Weighted average shares, basic millions of shares	58	74	78	101	152	162
Weighted average shares, diluted millions of shares	58	74	78	101	152	173

† Share count changed about 21x in the period ending 2021-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (NVAX's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021†Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	553	1,515	1,337	569	530	241
Marketable securities	158	0	—	0	393	494
Inventory	—	9	37	42	9	12
Prepaid and other current assets	181	174	237	226	78	27
Total current assets	1,248	2,155	1,703	1,144	1,129	978
Property and equipment, net	180	229	294	306	138	45
Right-of-use asset	8	40	36	25	22	20
Goodwill	135	131	126	127	107	113
Total assets	1,582	2,577	2,259	1,797	1,560	1,177
Accounts payable	54	127	217	133	42	25
Accrued liabilities	137	674	591	395	211	107
Total current liabilities	580	2,390	2,460	1,635	1,154	460
Lease liability, non-current	10	39	50	29	23	19
Total liabilities	955	2,928	2,893	2,514	2,184	1,304
Accumulated deficit	(1,874)	(3,618)	(4,276)	(4,821)	(5,008)	(4,568)
Total stockholders' equity	627	(352)	(634)	(717)	(624)	(128)
Total liabilities and equity	1,582	2,577	2,259	1,797	1,560	1,177
Common shares outstanding (cover page)‡ millions of shares	4	76	86	140	161	163

‡ Per-share figures and share counts are adjusted for the 1-for-20 stock split (December 2021); filings made before it reported them unadjusted.
† Share count changed about 21x in the period ending 2021-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (NVAX's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021†Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(418)	(1,744)	(658)	(545)	(187)	440
Stock-based compensation	128	184	130	85	48	36
Depreciation and amortization	4	13	29	41	48	28
Net cash from operating activities	(43)	323	(416)	(714)	(87)	(245)
Net cash from investing activities	(378)	100	(93)	(59)	(204)	(78)
Proceeds from issuing common stock	876	565	249	360	263	0
Net cash from financing activities	985	462	325	4	261	28
Net change in cash	567	880	(179)	(765)	(39)	(289)

† Share count changed about 21x in the period ending 2021-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Novavax	191	57	(73)*	164.9M	9.9 quarters	Q2 FY26 10-QJun 30, 2026
Harrow	84	71	(9.8)*	37.5M	8.6 quarters	Q2 FY26 10-QJun 30, 2026
Aurinia Pharmaceuticals	46	84	46*	134.0M	—	Q3 FY26 10-QSep 30, 2026
Neogen	172	223	13	218.3M	—	Q1 FY27 10-QAug 31, 2026
Akebia Therapeutics	156	49	3.5*	277.1M	—	Q2 FY26 10-QJun 30, 2026
Viridian Therapeutics	173	26	(93)*	113.6M	9.0 quarters	Q3 FY26 10-QSep 30, 2026
Spyre Therapeutics	83	not reported	(77)*	95.0M	15.7 quarters	Q3 FY26 10-QSep 30, 2026
Collegium Pharmaceutical	129	200	71*	32.6M	—	Q2 FY26 10-QJun 30, 2026
Ardelyx	46	128	2.2*	251.4M	—	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.